Replies to post #207685 on Biotech Values

[biomaven0]

Note Fibrogen has some potentially blocking patents in the US - no idea whether they will hold up - I have always assumed not.

Here's one:

The present invention relates to methods for treating anemia in a subject having a low percent transferrin saturation by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=30&f=G&l=50&co1=AND&d=PTXT&s1=fibrogen.ASNM.&OS=AN/fibrogen&RS=AN/fibrogen

[DewDiligence]

AMGN/SNY/REGN—US District Court extends stay on injunction an additional 15 days (from 30 days to 45 days):

http://finance.yahoo.com/news/amgen-statement-january-9-2017-232100039.html

SNY/REGN asked the Court to say the injunction pending the appeal, but this motion was denied.